Actively Recruiting
Evaluating Safety and Effects of Sotatercept in Japanese Children Aged 1 to 17 with Pulmonary Arterial Hypertension Receiving Standard Treatment
Led by Merck Sharp & Dohme LLC · Updated on 2026-10-06
6
Participants Needed
3
Research Sites
103 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying sotatercept in Japanese children aged 1 to less than 18 years who have pulmonary arterial hypertension PAH, a condition affecting blood vessels in the lungs. The study aims to evaluate the safety, tolerability, how the drug behaves in the body over time, and whether it reduces resistance in lung blood vessels while being taken alongside standard PAH treatments. Participants will receive sotatercept by subcutaneous injection every three weeks for about 24 weeks, starting at a dose of 0.3 mgkg. Depending on response and protocol guidance, the dose may increase to 0.7 mgkg starting at week 6. After 24 weeks, those who qualify may continue treatment for up to 58 months. All participants will continue their usual PAH therapy during the study. Throughout the trial, participants will be closely monitored with laboratory tests including blood counts, blood pressure measurements, and assessments of antibodies against the drug. Researchers will track adverse events, study drug levels in the blood, and changes in pulmonary vascular resistance. Secondary measures include exercise capacity and heart-related biomarkers. The study involves regular visits and evaluations over the treatment and extension periods to assess safety and effects.
CONDITIONS
Brief Title
A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032)
Research Team
T
Toll Free Number
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here